Table 1 Main input parameters of CEA model

Sarcopenia prevalence in Iran

0.245

±0.08

Beta

[24]

Annual discount rate

0.05

(0.03–0.12)

Beta

Time Horizon (years)

25

 EWGSOP

1

–

Beta

[32] and Table S1

 SarSA-Mod

0.806

(0.767–0.842)

Beta

[32] and Table S1

 MSRA

0.804

±0.08

Beta

[31]

 SARC-F

0.168

(0.135–0.206)

Beta

[32] and Table S1

 EWGSOP

0.84

(0.816–0.862)

Beta

[32] and Table S1

 SarSA-Mod

0.788

(0.75–0.803)

Beta

[32] and Table S1

 MSRA

0.604

(0.543–0.664)

Beta

[31]

 SARC-F

0.866

(0.843–0.886)

Beta

[32] and Table S1

 Probability of death in non-sarcopenic individuals (Normal Pop 60 yrs)

0.09

Beta

IRI Life Table

 Probability of death in sarcopenic individuals

0.132

±0.013

Beta

[37, 38]

 Probability of death in sarcopenic individuals with cardiovascular disease

0.198

±0.03

Beta

[37, 38] And Calibration

 Probability of death for sarcopenic individuals with fracture

0.171

±0.02

Beta

[37, 38] And Experts opinion

 Probability of falling in sarcopenic individuals

0.273

±0.03

Beta

[39,40,41]

 Probability of fracture in sarcopenic individuals

0.40

±0.05

Beta

[37]

 Probability of cardiovascular disease (CVDs) in sarcopenic individuals

0.27

±0.03

Beta

[12] And Experts opinion

 Annual average cost of treatment interventions (vitamin D, Supplements, exercise, diet)

1119.048

±119.047

Gamma

Survey and Calibration

 Cost of usual gait speed test

0.714

Gamma

Survey and Calibration

 Cost of handgrip strength test

1.309

Gamma

Survey and Calibration

 Cost of DXA

42.857

Gamma

Survey and Calibration

 Cost of MSRA

0.714

Gamma

Survey and Calibration

 Cost of SARC-F

0.714

Gamma

Survey and Calibration

 Cost of SARC-F (high-risk individuals)

44.880

Gamma

Survey and Calibration

 Cost of SarSA-mod

1.785

Gamma

Survey and Calibration

 EWGSOP (stage 1)

2.023

Gamma

Survey and Calibration

 EWGSOP (stage 2)

42.857

Gamma

Survey and Calibration

 Cost of treatment and care of fractures

3599.048

±695.074

Gamma

Survey and Calibration

 The initial average per capita cost of treatment and care of cardiovascular patients

4149.286

Gamma

Survey and Calibration

 The incremental average per capita cost of treatment and care of cardiovascular patients

1904.762

±190.476

Gamma

Survey and Calibration

 Non-sarcopenic individuals (Normal Pop > 60 yrs)

0.76

Beta

[42, 43]

 Sarcopenic individuals

0.68

Beta

[44]

 Sarcopenic individuals with fracture

0.51

Beta

[40, 44, 45]

 Sarcopenic individuals with cardiovascular disease

0.56

Beta

[44, 46]

 Sarcopenic individuals with cardiovascular disease and fracture

0.42

Beta

[44,45,46,47]

 Efficacy of sarcopenia interventions (vitamin D, Supplements, exercise, diet)

40%

±15%

Beta

[48,49,50]